● Recruiting

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Condition: Gastroesophageal Junction (GEJ) Adenocarcinoma · Sponsor: National Cancer Center Hospital East

PhasePhase 2

Planned participants26

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ preservation treatment strategies.

This description comes directly from the study's public registry record.

Talk to the study team

Kohei Shitara, MD · +81-4-7133-1111 · pemflot-tnt@east.ncc.go.jp

Izuma Nakayama, MD · +81-4-7133-1111 · pemflot-tnt@east.ncc.go.jp

Always discuss trial participation with your own doctor first.

Locations (1)

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07018570